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Summary Squamous cell carcinomas of the anus are rare neoplasias that account for about 3% of large bowel tumours. Infections with
human papillomaviruses are frequently detected in these cancers, suggesting that pathogenic pathways in anal carcinomas and in
carcinomas of the uterine cervix are similar. Little is known regarding recurrent chromosomal aberrations in this subgroup of squamous cell
carcinomas. We have applied comparative genomic hybridization to identify chromosomal gains and losses in 23 cases of anal carcinomas.
A non-random copy number increase of chromosomes 17 and 19, and chromosome arm 3q was observed. Consistent losses were mapped
to chromosome arms 4p, 11q, 13q and 18q. A majority of the tumours were aneuploid, and most of them showed increased proliferative
activity as determined by staining for Ki-67 antigen. p53 expression was low or undetectable, and expression of p21/WAF-1 was increased in
most tumours. Sixteen cancers were satisfactorily tested for the presence of HPV by consensus Li -primer polymerase chain reaction; nine
were HPV positive, of which eight were positive for HPV 16.
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Comparative genomic hybridization (CGH) serves as a cytoge-
netic screening test that allows the mapping ofchromosomal copy
number changes in tumour genomes on normal metaphase chro-
mosomes (Kallioniemi et al; 1992). Only genomic tumour DNA is
required for analysis. Consequently, CGH can be performed using
DNA extracted from formalin-fixed and paraffin-embedded speci-
mens (Speicher et al, 1993; Isola et al, 1994). This feature allows
the retrospective determination of chromosomal aberrations in
archived tumour material (Ried et al, 1995). CGH is a well-suited
tool to compare chromosomal aberrations with additional pertinent
characteristics of specific tumours, such as histology, DNA ploidy
and immunohistochemistry (Heselmeyer et al, 1996; Ried et al,
1996). We have recently established a phenotype-genotype corre-
lation in the genesis ofHPV-positive squamous cell carcinomas of
the cervix uteri (Heselmeyer et al, 1996, 1997). We observed a
characteristic pattern ofgenetic and phenotypic changes that were
specific for cervical carcinogenesis: the gain of the long arm of
chromosome 3 occurred in virtually all HPV-positive, aneuploid
invasive carcinomas; and low expression ofp53 was accompanied
by high levels of p21/WAF-1. In order to understand whether the
observed genotype-phenotype pattern represents a common
pathogenic pathway in HPV-induced squamous cell carcinomas,
we have extended the CGH analysis to squamous cell carcinomas
of the anus. Anal squamous cell carcinomas are rare tumours for
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which natural history is incompletely understood (Williams et al,
1994). It is clear, however, that HPV genomes are frequently
detected in these tumours and their precursor lesions (Zaki et al,
1992; Heino et al, 1993; Palefsky, 1994) and that cervical and anal
cancers have similar risk factors and pathology (IARC mono-
graph, 1995). Only a few reports on the cytogenetics ofanal carci-
nomas are available. Muleris et al (1987) identified the recurrent
loss of chromosome arms 3p and 1 lq in a series of eight tumours
(Muleris et al, 1987). We used CGH to screen 23 carcinomas ofthe
anus for chromosomal copy number changes. The same tumour
section that was used for CGH was analysed for the presence of
HPV genomes. Adjacent serial sections were examined for crude
DNA ploidy by image cytometry, for proliferative activity (MIB-
1), for the expression level of the tumour-suppressor gene TP53
and the cyclin-dependent kinase inhibitor p21/WAFl.
MATERIALS AND METHODS
Tissue microdissection and DNA extraction
Tumour material was collected at hospitals throughout Sweden
between 1985 and 1989 and diagnosed on haematoxylin and
eosin-stained tissue sections. The clinical data are summarized in
Table 1. Consecutive sections were prepared from each sample and
used for histological diagnosis (4,m thick), DNA ploidy
measurement (8 ,um), immunohistochemistry (4 jim) and genomic
DNA extraction (50 jm). A second 4-jm section was stained to
confirm the presence of tumour tissue. All analyses were
performed on these samples.
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Table 1 Summary of the clinical and histomorphological data for 23 anal carcinomas
Case no. List no. Age Sex Location Size (cm) Stage Histologic type Differentiation
1 Tl 83 M Anal 3 x 2 pT2, pNO, MO Squamous Poor
2 T5 79 M Anal 4 x 6 pT3, pNl, MO Squamous Moderate
3 T6 71 F Anal 3 x 1 x 1 pT2, pNO, MO Squamous Moderate
4 T8 81 F Anal 5 x 8 pT4, pNl, Ml Basaloid High
5 T9 82 F Perianal 2.5 x 1.5 pT2, pNO, MO Basaloid High
6 T10 70 M Anal 2 x 9 pT3, pNO, Ml Basaloid High
7 T1l 74 F Anal 5.5 x 4 pT3, pNO, MO Basaloid High
8 T12 53 F Anal 4 x 3 pT2, pNO, MO Squamous High
9 T13 63 F Perianal 2 pTl, pNO, MO Squamous High
10 T14 63 F Anal 3 x 3 pT2, pNO, MO Basaloid High
11 T16 83 F Anal 10 x 10 pT3, pNO, MO Squamous High
12 T17 62 F Anal 3 x 0.5 pT2, pNO, MO Basaloid High
13 T18 66 F Anal 1 x 1 pTl, pNO, MO Basaloid High
14 T20 76 M Anal 2 x 1 pT2, pNO, MO Squamous Moderate
15 T22 37 F Perianal 2 x 1 x 1 pTl, pNO, MO Squamous High
16 T28 77 M Perianal 2 x 2 pT2, pNO, MO Squamous High
17 T29 66 F Perianal 1 x 1 pTl, pNO, MO Squamous High
18 T31 38 M Anal 2 x 3 pT2, pNO, MO Squamous High
19 T32 67 F Anal 5 x 5 pT3, pNO, MO Squamous Poor
20 T33 36 F Anal 8 x 4 pT4, pNl, MO Squamous High
21 T34 52 F Anal 4 pT2, pNO, MO Squamous Moderate
22 T35 51 M Anal 2.5 x 1.5 pT2, pNl, MO Basaloid High
23 T36 66 F Anal 4 x 3 pT2, pNO, MO Squamous High
DNA ploidy measurements
DNA content measurements were performed by image cytometry
of histological sections as described (Auer et al, 1989; Steinbeck
et al, 1995). All DNA values were expressed in relation to the
corresponding staining controls, which were given the value 2c,
denoting the normal diploid DNA content, and are presented in
relative units. The histograms were divided into five groups: (1)
diploid cases with a distinct peak in the normal 2c region and no
cells oronly a minor fraction ofcells (<5%) in the region between
2c and4c; (2)proliferating diploid cases with apeak in the normal
2c region and a fraction of cells (> 5%) between 2c and 4c; (3)
tetraploid cases with a main peak in the 4c region and no cells or
only a minor fraction of cells (<5%) exceeding Sc; (4) aneuploid/
proliferating tetraploid cases with a peak in the 4c region and a
fraction of 5-20% of the cells exceeding Sc; and (5) aneuploid
cases with a mainpeak around the 4cregion and more than 20% of
the cells exceeding Sc. Examples of the histograms are presented
in Figure 1.
Immunohistochemistry
Ki-67 antigen was detected with a monoclonal antibody, MIB-1
(Immunotech, Marseille, France). The antibody allows the
discrimination of non-proliferating (Go) cells from proliferating
cells (G,-S-G2-M). p21/WAF-I expression was analysed with the
WAF-I antibody EAlO (Oncogene Science), and p53 expression
was determined with the DO-1 antibody (Santa Cruz).
Immunohistochemistry was performed essentially as described
(Ried et al, 1996). Examples of the immunohistochemical staining
are presented in Figure 2.
HPV genotyping
HPV genomes in the purified specimen DNA were identified by
polymerase chain reaction (PCR) using the MY09-MY 11 LI
consensus primers for amplification (Bosch et al, 1995). Twenty-
five type-specific probes and a generic HPV probe were used to
diagnose the HPV type in the PCR products as described in detail
elsewhere (Hildesheim et al, 1994). P-Globin amplification was
performed to evaluate adequacy oftumour DNA.
CGH
CGH was performed on normal metaphase chromosomes prepared
after standard procedures. Control DNA was labelled with digoxi-
genin dUTP (Boehringer Mannheim) by nick translation. Tumour
DNA was extracted from 50-im formalin-fixed tissue sections.
The tissues were dewaxed in xylene and washed in ethanol. The
sections were incubated overnight in 1 M sodium-isothiocyanate at
37°C, washed twice in phosphate-suffered saline (PBS) and incu-
bated in DNA extraction buffer (75 mM sodium chloride, 25 mM
EDTA, 0.5% Tween). Proteinase K was added to a final concentra-
tion of 1 mg ml-'. The DNA was phenol extracted and precipitated
in ethanol.
Labelling was performed by nick translation substituting dTTP
bybiotin-16-dUTP(BoehringerMannheim). Ofeach differentially
labelled genome, 500 ng was precipitated together with an excess
(30 jg) of the Cot-I fraction of human DNA (Gibco BRL). The
probe DNA was resuspended in 10g1 of hybridization solution
(50% formamide, 2 x standard saline citrate (SSC), 10% dextran
sulphate), denatured (5 min, 75°C) and preannealed for 1 h at
37°C. The normal metaphase chromosomes were denatured sepa-
rately (70% formamide, 2 x SSC) for 2 min at 75°C and dehy-
drated through an ethanol series. Hybridization took place under a
coverslip for 2-4 days at 37°C. Post-hybridization washes and
immunocytochemical detection was performed as described
(Heselmeyer et al, 1996). Biotin-labelled tumour sequences were
detected with avidin conjugated to FITC (Vector laboratories), and
the digoxigenin-labelled reference DNA was developed using a
mouse anti-digoxigenin antibody, followed by a TRITC-conju-
gated anti-mouse antibody (Sigma Chemicals). The slides were
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Figure 1 Representative examples of DNA histograms in anal squamous
cell carcinomas. The histograms were divided in five groups: (A) diploid
histograms; (B) proliferating diploid; (C) tetraploid; (D) aneuploid/proliferating
tetraploid; and (E) aneuploid. For classification of the histograms see
Materials and methods
counterstained with DAPI and embedded in an antifade solution
containing DABCO.
Microscopy and image analysis
Grey-level images were acquired for each fluorochrome with a
cooled CCD camera (Photometrics, Tucson, AZ, USA) coupled to
a Leica DMRBE epifluorescence microscope using sequential
exposure through fluorochrome specific filters (TRI, TR2, TR3,
Chroma Technology). Chromosomes were identified using DAPI-
banding. Fluorescence ratio images were calculated by a custom
computerprogram (du Manoir et al, 1995) and run on a Macintosh
Quadra 950 (Figure 2D and F). Average ratio profiles were calcu-
lated from at least eight ratio images. After the determination of
the chromosomal axis for each chromosome in every metaphase,
individual FITC and TRITC profiles were calculated. These were
used for the computation of the ratio (FITC/TRITC) profiles. The
three vertical lines on the right side of the chromosome ideogram
represent different values of the fluorescence ratios between the
tumour and the normal DNA (Figure 3). The values are 0.75, 1 and
1.25 from left to right. These values were chosen as thresholds for
the identification ofDNA copy numberdecreases (below 0.75) and
increases (above 1.25) as described in du Manoir et al (1995). The
curve shows the ratio profiles that were computed as mean values
ofat least eight metaphase spreads. Average ratio profiles were the
basis for all evaluations.
RESULTS
CGH was used to identify chromosomal copy numberchanges in a
series of 23 anal squamous cell carcinomas. The clinical data are
presented in Table 1. The molecular cytogenetic analysis was
complemented by HPV genotyping and DNA ploidy measure-
ments. The proliferative activity and the expression levels of the
tumour-suppressor gene p53 and the cyclin-dependent kinase
inhibitor p21/WAF-1 were analysed on the same tissue sections.
The combined data allow for a phenotype/genotype correlation in
this rare subgroup of squamous cell carcinomas. Table 2 summa-
rizes the data.
CGH
The CGH analysis revealed a recurrent pattem of chromosomal
gains and losses. Figure 2D and F presents ratio images from
tumours 5 and 8. An average ratio profile for case 8 is presented in
Figure 3. The average ratio profile was used for the identification
of copy number changes in all cases. The karyogram of chromo-
somal gains and losses is summarized in Figure 4. Chromosomal
gains were mapped to chromosome 19 (14 of 23 cases), chromo-
some 17 (9 of23 cases), chromosome 3q (7 of23 cases) and chro-
mosome 22 (5 of 23 cases). Consistent losses occurred on
chromosomes 11 (9 of 23 cases), 18 (8 of 23 cases), 4p (7 of 23
cases) and 13 (6 of 23 cases). High-level copy number increases
were observed infrequently on chromosome 3q (two cases) and on
chromosome band 2p23-24. All tumours showed chromosomal
copy number alterations. In 23 tumours, 110 copy number changes
were observed, resulting in an average number ofcopy alterations
(ANCA) of 4.8. In 90 of 110 copy number changes (82%), entire
chromosomes or chromosome arms were subject to gain or loss.
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Figure 2 Examples of immunohistochemical detection of the Ki-67 antigen, p53 and p21/WAF-1 expression in case 8 (A-C) and 5 (E-G). Immunoreactive
nuclei appear dark brown. The tissue was counterstained with haematoxylin and eosin, which appears blue. The CGH ratio images of these cases are displayed
in D and H. Blue indicates a balance between tumour and test genomes, red reflects a loss of genetic material in the tumour DNA and green shows regions that
are gained in the tumour. Case 5 reveals increased proliferative activity, intense staining with the DO-1 antibody and low reactivity with the antibody against
p21/WAF-1. Case 8, however, revealed a pattern that was recurrently observed in anal cell carcinomas, i.e. increased proliferative activity, undetectable p53
staining and high expression of p21/WAF-1
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Figure 3 Identification of copy number changes by CGH. Average ratio
profile of case 8. The three vertical lines on the right side of the chromosome
ideograms reflect different values of the fluorescence ratio between the tumor
and the normal DNA. The values are 0.75, 1 and 1.25 from left to right. The
ratio profile (curve) was calculated as a mean value of at least eight
metaphase spreads. Copy number changes are present on chromosome
3q,19 and 22 (gains) and 4p and 11 (losses)
HPV genotyping
HPV genotyping was performed on the genomic tumour DNA that
was used for CGH as described. Seven tumour DNAs in which P-
globin could not be amplified were scored as unsatisfactory. In the
remaining sixteen tumours, HPV 16 was detected in eight
tumours; in one tumour, the HPV type could not be identified.
Seven tumours were negative for HPV. Aneuploid DNA
histograms were seen in six of seven HPV-positive and four of
seven HPV-negative tumours. The data are summarized in Table 2.
DNA ploidy
The majority ofthe cases studied by image cytometry on consecu-
tive sections revealed an aneuploid DNA histogram with a main
peak in the tetraploid region (4c) and more than 20% of the cells
exceeding Sc. Only two of the anal carcinomas remained diploid.
One ofthe diploid tumours revealed, as a sole anomaly, the loss of
one X chromosome. However, the second diploid tumour showed
multiple chromosomal aberrations. Three tumours revealed a clear
tetraploidization with peak values between 3.9c and 4.Ic. There
was no obvious correlation between the number ofcopy alterations
and the ploidy. Examples ofthe histograms are presented in Figure
1 and a summary ofthe ploidy measurements is given in Table 2.
Immunohistochemistry
Proliferative activity and p53 and p21/WAF-1 expression levels
were investigated immunohistochemically. Seventeen of 23
tumours revealed increased proliferative activity, with more than
60% of the cells showing positive staining with an antibody
against Ki-67. Increased immunoreactivity for p53 was low or not
detectable with the exception of one case, in which 90% of the
cells showed immunoreactivity (case 5). The percentage of the
cells that stained positively with an antibody directed against
p21/WAF-1 ranged from 20% to 90%, with most of the cases
showing moderately to highly increased reactivity in 40-60% of
the cells. Immunoreactivity was not detected in one case (case 5)
in which p53 expression was high, suggesting the presence of
mutated TP53. Figure 2 presents examples of the immunohisto-
chemistry of case 8, which exemplifies the consistent staining
pattern, and of case 5, which revealed an exceptional immuno-
staining. A summary ofthe quantification is provided in Table 2.
DISCUSSION
We conducted a molecular cytogenetic study of 23 cases of anal
squamous cell carcinomas by CGH. The cytogenetic data were
complemented by DNA ploidy measurements, HPV genotyping
and expression level analysis of the proliferation marker Ki-67, the
tumour-suppressor gene product p53 and the cyclin-dependent
kinase inhibitor p21/WAF-l. CGH analysis revealed a recurrent
pattern ofchromosomal gains and losses. Chromosomes 11, 18, 13
and 4p were most frequently under-represented, whereas copy
numbergains were consistently mapped tochromosomes 19, 17 and
3q. It should be noted that copy number changes involving chromo-
some 19 require cautious interpretation ifthey occur simultaneously
with changes on chromosomes lp, 16 and 22. These chromosomal
regions are known to be rich in Alu-repeat sequences, which may
cause unspecific ratio variations. However, chromosome 19 was
independently subjected to copy number increases. In three
instances, high-level copy number increases (amplifications) were
identified on chromosome arm 3q and or chromosomal bands
3q26-28 and 2p23-24. The amplification on 2p24 coincides with
the chromosomal mapping position of the N-myc proto-oncogene.
Reports on chromosomal aberrations by means of chromosome
banding analyses are rare. Muleris et al (1987) reported the non-
random loss ofchromosomes 3p and 1lq. While chromosome 3p is
affected in only 2 of 23 cases in our study, the loss ofchromosome
1lq occurs in 9 of 23 of our cases. The minimally deleted region
encompasses chromosome bands 1 Iq14-25. The recurrent loss of
this chromosomal region suggests that this region harbours a
tumour-suppressor gene involved in the genesis of anal squamous
cell carcinomas. The average number of copy alterations (ANCA)
amounts to 4.8 per tumour. In a previously performed series of
stage TI cervical carcinomas, the ANCA per tumour was 4.0
(Heselmeyer et al, 1996). No correlation between the ANCA per
tumour and the ploidy, the presence of HPV infection or the differ-
entiation and tumour stage was obvious in anal squamous cell carci-
nomas. The immunohistochemical analysis of the same samples
that were used for CGH revealed a consistent pattern: in the
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Table 2 Summary of the results from MIB-1, DO-1, WAF-1 staining, DNA ploidy measurements, HPV genotyping and CGH in anal carcinomas
Case List MIBl DOI WAF1/p21 DNA HPV CGH
no. no. (Ki-67) (p53) (%) ploidy
(% (%)
1 Ti 80 < 2 60 A 16 + + 3q, -4p, -8p-i1q12-ter,
-15, -16, -17, -20, -21
2 T5 80 Neg 80 T Neg + 5p, + 3q, -1Oq, -11, -13q,
-18, + 19
3 T6 90 Neg 90 ND Uns -4p, -5p, -8q23-ter, -11, + 19,
-20, -21
4 T8 90 < 2 20 A Neg -2q14.2-32, -11q, -14q
5 T9 60 90 Neg A/pT Neg + +2p23-24, -8q23-ter,
-18q22-ter, + 19
6 T10 80 Neg 70 A 16 + 3q, + 5q, + 6p, -8p12-ter, + 9, -11q,
-13q21-ter, + 16p, + 17, + 19, + 22, + X
7 Tll 40 < 2 70 A Neg -8p2i-ter
8 T12 90 5 50 A Neg + 3q, -4p, -11, + 19, + 22
9 T13 20 < 2 60 D Neg -x
10 T14 50 Neg 90 A 16 + 1, + 3q, -4p, -11, + 16p,
+ 17centr.-q22, + 19, + 22
11 T16 50 Neg 80 A 16 -3p, -10, -18q12-ter
12 T17 90 Neg 40 A 16 + 3q(+ + 3q26-ter), -4p, + 9q,
-11q14-ter, -13q, + 17
-18q, + 19, + 22
13 T18 90 Neg <2 ND positive -3p22-centr., -7p, -9, -11q, + 19, -X
Type uns
14 T20 90 5 40 A 16 + 3q, + 12q, -13q, + 17, -18q, + X
15 T22 80 5 50 ND 16 + 17q, + 19
16 T28 80 5 5 D Neg -4p,-5p,-13q14-ter, + 17p12-q23
-18q12-ter, + 19
17 T29 50 50 50 pD Uns + 12q24,-13q
+ 15qcentr-23, + 16, + 17,
-18, + 19, + 22
18 T31 80 Neg 40 A Uns -4p, -5p, + 19
19 T32 80 20 60 A Uns + 12q
20 T33 40 < 2 80 A Uns + 17, -18q, + 19
21 T34 70 < 2 20 A Uns -x
22 T35 80 Neg 20 T Uns + 12q, + X
23 T36 80 < 2 20 T 16 + 12q24, + 16p, + 17, + 19
MIB-1, DO-1 and WAF-1 immunohistochemical results are presented as percentages of the tumour cells that reacted with the respective antibody. DNA
histograms are classified as diploid (D), proliferating diploid (pD), tetraploid (T), aneuploid/proliferating tetraploid (A/pT) and aneuploid (A) (see also Figure 1)
The HPV types are provided as determined by dot blot analysis: neg, negative for detection of HPV sequences; uns, unsatisfactory. The CGH column shows the
chromosomal aberrations detected in individual cases.
majority of the cases, the proliferative activity was notably
increased. In all but one case (case 5), immunoreactivity for p53
was low or not detectable. However, p21/WAF-1 expression levels
were high. The low levels ofimmunoreactivity ofp53 may reflect
that the mutation inactivation of TP53 is not essential in anal
squamous cellcarcinogenesis.Interestingly, deletion ofthechromo-
somal mapping position of TP53 on chromosome 17p was only
observed in one case. In contrast, chromosome 17 is frequently
gained. The consistent overexpression ofp21/WAF-l corroborates
this finding, because TP53 mutation inactivation would result in the
interruption of the downstream pathway for p21/WAF-l activation
and would therefore result in low levels ofp21/WAF-1, a pattern
that we observed consistently in colon carcinogenesis (Ried et al,
1996). It is not clear whether the strong expression ofp21/WAF-l
indicates that the inactivation ofp53 via the E6 protein of HPV is
incomplete (Butz et al, 1995) or whether p21/WAF-l expression is
up-regulated using alternate regulatory pathways (Parker et al,
1995; Chin et al, 1996). p53 expression levels show no correlation
with HPV infection.
We have previously established a phenotype-genotype correla-
tion in cervical and colon carcinogenesis (Heselmeyer et al, 1996;
Ried et al, 1996). When comparing the results from these studies,
the following conclusions become apparent: the acquisition of
multiple chromosomal aberrations that occur in colon carcinomas is
accompanied by high-level p53 expression and concomitant low-
level expression or negativity for p2l/WAF-I activity. In cervical
carcinomas, however, the acquisition of numerous chromosomal
aberrations that occur atthethresholdfrompremalignanthigh-grade
dysplasias to invasive carcinomas is not related to mutant p53
expression, and p21/WAF-1 activity remains elevated. However,
HPV 16 (and other high-risk subtypes) are almost invariably
observed. While HPV infection does not seem as common in anal
squamous cell carcinomas, the phenotypic changes are strikingly
similar: p53 is virtually non-detectable (with the exception of case
5) andp2l/WAF-1levels are elevated. Theobservedsimilarity inthe
pattern of phenotypic and genotypic changes in cervical and anal
squamous cell carcinomas led us to conclude thatitdiscloses consis-
tent features ofHPV-related squamous cell carcinogenesis.
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Figure 4 Karyogram of chromosomal gains and losses in squamous anal cell carcinomas. Bars on the right side of the chromosome ideogram indicate a gain
and bars on the left side a loss of genetic material. Solid bars denote high-level copy number increases (amplifications). Individual tumour samples can be
identified by case numbers
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